Pantoprazol Azevedos (Pantoprazole)

Pantoprazol Azevedos is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis.
• Erosive gastritis and duodenal ulcer disease: accelerates ulcer healing and reduces recurrence.
• Prevention of stress‑related mucosal damage in critically‑ill patients: lowers the risk of gastrointestinal bleeding.
• Hyper‑secretory conditions such as Zollinger‑Ellison syndrome: controls excessive gastric acid output.
• Use in combination with antibiotics for eradication of *Helicobacter pylori* infection: enhances eradication rates when part of a triple‑therapy regimen.

• Pantoprazole selectively and irreversibly inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid production, it markedly reduces both basal and stimulated gastric acid secretion, allowing the gastrointestinal mucosa to heal and decreasing acid‑related symptoms.

Pantoprazol Azevedos may cause adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually transient.
• Nausea or abdominal discomfort: occasional.
• Flatulence: occasional.
• Mild elevation of liver enzymes: typically asymptomatic.

Serious or Rare Side Effects

• Severe hypersensitivity reactions (e.g., anaphylaxis, Stevens‑Johnson syndrome).
• Clostridioides difficile‑associated colitis.
• Acute interstitial nephritis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Osteoporotic fractures with long‑term therapy.
• Liver dysfunction or hepatitis.

Pantoprazol Azevedos should be used with consideration of patient‑specific factors and monitoring requirements.

• Renal impairment: dose adjustment may be needed in severe renal dysfunction.
• Hepatic impairment: use with caution in patients with moderate to severe liver disease.
• Long‑term therapy: monitor bone health and magnesium levels periodically.
• Concomitant antibiotics: assess for potential interaction when used in *H. pylori* eradication regimens.
• Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk.
• Store at room temperature: keep in the original container, protect from light and moisture.

Pantoprazol Azevedos can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption due to increased gastric pH.
• HIV protease inhibitors (e.g., atazanavir): markedly decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of INR; monitor coagulation parameters.
• Methotrexate: increased serum levels, especially with high‑dose regimens.
• Digoxin: possible increase in serum concentration.